2379 |
Serial Follow-up Imaging of Bioresorbable Vascular Scaffolds and Clinical Implication |
Patrick W. Serruys |
Apr. 20. 15 |
2378 |
What to Do with Functionally Insignificant Vulnerable Plaque? |
Evelyn Regar |
Apr. 20. 15 |
2377 |
How to Detect and Treat Vulnerable Plaques?: Results with NIRS-IVUS |
James E. Muller |
Apr. 20. 15 |
2376 |
[TCTAP A-123] Mitral Loop Cerclage (MLC) as a Variant from of \'Mitral Cerclage Annuloplasty\' by Adding an Appliance (CSTV) for Preventing Its Potential Complications: A Preclinical Study with Mature Devices |
June Hong Kim |
Apr. 20. 15 |
2375 |
Detection and Implication of Plaque Erosion As a Cause of Coronary Thrombosis |
Ik-Kyung Jang |
Apr. 20. 15 |
2374 |
Future Roadmap of the Mitral Valve Therapies |
Gregg W. Stone |
Apr. 20. 15 |
2373 |
Vulnerable Plaque Imaging: Learn from PROSPECT, ATHEROREMO and VIVA |
Gary S. Mintz |
Apr. 20. 15 |
2372 |
Transcatheter Therapies for Mitral Regurgitation |
Jian (James) Ye |
Apr. 20. 15 |
2371 |
Natural History of Vulnerable Plaque: Targets for Risk Stratification |
Renu Virmani |
Apr. 20. 15 |
2370 |
Current Status of Transcatheter Therapies for Mitral Regurgitation |
Ted Feldman |
Apr. 20. 15 |